Conventional immunotherapy has been developed to initiate a successful antitumor T cell response through strengthening DC ability to prime both CD4+ and CD8+ T cell activation, enhancing T cell trafficking and infiltration into the tumor bed and inhibiting by immunosuppressive cells (TAMs, MDSCs, and Tregs) in the tumor microenvironment (55, 122). Here, CD8A is linked to neoplasm.